Overview

A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

Status:
Terminated
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
Phase:
Phase 3
Details
Lead Sponsor:
Mundipharma Research Limited
Treatments:
Bendamustine Hydrochloride
Rituximab